Regulatory changes are paving the way for speedier access to biosimilars in the US, while gain-share agreements are driving strong adoption rates in Europe.
Despite many bumps in the road and a lack of clear direction, the US healthcare ecosystem always finds a way to deliver its goal – improving the health and well-being of every American